Table 2. Circulatory miRNAs as potential biomarkers for Colorectal Cancer (CRC).

Application	miRNA biomarker	Type of analysis*	Total nr of samples#	Ref.
	MIRNA BIOMARKERS IN SERUM/PLASMA		specimens #1
Anti-angiogenetic therapy	miR-126	↑, SNP	178	[256]
Anti-EGFR therapy	miR-345	↑	138	[257]
Chemotherapy	miR-19a	↑	88	[258]
	miR-20a, miR-130, miR-145, miR-216, miR-372	signature	253	[118]
	miR-27b, miR-148a, miR-326, miR-106a, miR-484, miR-130b	signature	328	[259]
	miR-126	↑	178	[260]
	miR-143	↓	51(175)	[185]
	miR-155, miR-200c, miR-210	↑	35	[261]
Diagnosis	miR-17-3p, miR-29a, miR-92a, miR-135b	expression, not significant	130	[262]
	miR-18a, miR-19a, miR-19b, miR-15b, miR-29a, miR-335	signature	196	[263]
	miR-19a-3p, miR-223-3p, miR-92a-3p, miR-422a	signature	697	[264]
	miR-21	↑	5 studies	[62]
	miR-21	↑	366(532)	[265]
	miR-21	↑	100(192)	[59]
	miR-21	↑	75(189)	[60]
	miR-21	↑	80	[266]
	miR-21	↑	71	[267]
	miR-21, let-7g, miR-31, miR-92a, miR-181b, miR-203	signature	202	[268]
	miR-21, miR-378	↑	135	[269]
	miR-21, miR-92a	↑	98	[270]
	miR-29a, miR-92	↑	216	[271]
	miR-34a	↓	108	[272]
	miR-92	↑	255(265)	[273]
	miR-145	↓	50(170)	[274]
	miR-145	↓	60	[275]
	miR-193a-3p, miR-23a, miR-338-5p	signature	162(222)	[276]
	miR-375, miR-206, miR-150, miR-125b, miR-126*	↓	140(228)	[277]
	miR-409-3p, miR-7, miR-93	signature	241	[278]
	miR-423-5p, miR-210, miR-720, miR-320a, miR-378, miR-106a, miR-143, miR-103, miR-199a-3p, miR-382, miR-151-5p	signature	90	[279]
	miR-423-5p, miR-484	, diverse	103	[280]
	miR-532-3p, miR-331, miR-195, miR-17, miR-142-3p, miR-15b, miR-532, miR-652, miR-431, miR-15b, miR-139-3p	signature	128	[281]
	miR-574-5p	↑	14(146)	[281]
	miR-601, miR-760	↓	191	[282]
Prognosis/Survival/ Metastasis	miR-7, miR-17-3p, miR-20a, miR-21, miR-92a, miR-96, miR-183, miR196a and miR-214, miR-124, miR-127-5p, miR-138, miR-143, miR-146a, miR-222	expression, diverse	20(40)	[283]
	miR-21	↑	102	[284]
	miR-124-5p, miR-26a	↓	71(142)	[285]
	miR-141	↑	278	[286]
	miR-155	↑	206	[287]
	miR-182	↑	51(161)	[66]
	miR-200c	↑	230(446)	[288]
	miR-218	↓	90(331)	[289]
	miR-221	↑	140	[61]
	miR-23a	↑	102(162)	[290]
	miR-29a, miR-92a	↑, no associations for miR-92a	74(114)	[291]
	miR-92a	↑	56(94)	[292]
	let-7i, miR-10b, miR-221, miR-320a, miR-885-5p	signature	169(478)	[293]
	miR-126, Let-7a, miR-141, miR-21	signature	224	[294]
	miR-15a, mir-103, miR-148a, miR-320a, miR-451, miR-596	signature	40	[295]
	miR-18a, miR-29a	↑	56(80)	[296]
	miR-29c	↑	84(191)	[297]
	miR-148a	↓	85(195)	[298]
	miR-183	↑	179(195)	[65]
	MIRNA BIOMARKERS IN STOOL		specimens #2
Diagnosis	miR-7, miR-17, miR-20a, miR-21, miR-92a, miR-96, miR-106a, miR-134, miR-183, miR-196a, miR-199a-3p, miR-214, miR-9, miR-29b, miR-127-5p, miR-138, miR-143, miR-146a, miR-222, miR-938	signature	60(75)	[299]
	miR-21, miR-106a	↑	37(42)	[300]
	miR-34b, miR-34c	methylation	122(286)	[301]
	miR-34b, miR-34c, miR-148a	methylation	67(189)	[302]
	miR-106a	↑	224	[303]
	miR-135b	↑	424(490)	[304]
	miR-143, miR-145	↓	51	[305]
	miR-144*	↑	75(105)	[306]
	miR-221, miR-18a	↑	595(675)	[307]
	miR-451, miR-223	↑	45(61)	[308]
	miR-J1-5p	↓	56(68)	[309]
	miR-21, miR-92a	↑	239(326)	[310]
	miR-135a, miR-135b, miR-18a, miR-19a	↑	340(402)	[311]
	miR-20a-5p, miR-21-3p, miR-141	↑	40(80)	[312]

* ↑, upregulated expression in CRC vs. normal control; ↓, downregulated expression in CRC vs. normal control; methylation, cancer specific DNA methylation; signature, multiple miRNAs considered collectively; expression, diverse, multiple miRNAs considered separately, #total number of samples included in the study, CRCs, adenomas and normal control samples collectively; specimens #1 – serum or plasma samples from healthy controls, individuals with adenomas and cancer patients, total number of samples, including tissue samples are given in parenthesis; specimens #2 - stool samples from healthy controls, individuals with adenomas and cancer patients, total number of samples, including tissue samples are given in parenthesis.